Cargando…
Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials
The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76–0.95, p = 0.004;...
Autores principales: | Barkas, Fotios, Anastasiou, Georgia, Milionis, Haralampos, Liberopoulos, Evangelos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179959/ https://www.ncbi.nlm.nih.gov/pubmed/34123693 http://dx.doi.org/10.1007/s13340-021-00515-4 |
Ejemplares similares
-
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021) -
Anakinra in COVID-19: A step closer to the cure
por: Barkas, Fotios, et al.
Publicado: (2022) -
A step-by-step guide for the diagnosis and management of hyponatraemia in
patients with stroke
por: Barkas, Fotios, et al.
Publicado: (2023) -
Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review
por: Barkas, Fotios, et al.
Publicado: (2021) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)